5 results found.

Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage IVA Colon Clinical Trial using ziv-aflibercept; leucovorin calcium; irinotecan hydrochloride; fluorouracil

City of Hope Medical Center - Recruiting 18 years or older.
- A Prospective Study of Short Infusion of Ziv-Aflibercept in Combination With FOLFIRI in Patients With Metastatic Colorectal Cancer.
ziv-aflibercept; leucovorin calcium; irinotecan hydrochloride; fluorouracil

Colorectal Cancer Clinical Trial using Exercise Program; Telephone-based intervention; Counseling intervention; Questionnaire administration; Relaxation Program

M.D. Anderson Cancer Center - Recruiting 18 years or older.
- Comparative Study of Oncologist Recommended, Home-Based Exercise Program and Relaxation Training for Physical Functioning and Symptom Control in Colon Cancer Patients.
Exercise Program; Telephone-based intervention; Counseling intervention; Questionnaire administration; Relaxation Program

Adenomatous Polyp, Colon Cancer, Stage IIA Colon Cancer, Stage II Clinical Trial using defined green tea catechin extract; placebo; laboratory biomarker analysis; questionnaire administration

National Cancer Institute (NCI) - Recruiting 40 years or older.
- Randomized Phase II Trial of Polyphenon E vs. Placebo in Patients at High Risk of Recurrent Colonic Neoplasia.
defined green tea catechin extract; placebo; laboratory biomarker analysis; questionnaire administration

Mucinous Adenocarcinoma of the Colon, Mucinous Adenocarcinoma of Clinical Trial using panitumumab; irinotecan hydrochloride; fluorouracil; leucovorin calcium

Ohio State University Comprehensive Cancer Center - Recruiting 18 years or older.
- A Phase II Study of Panitumumab in Combination With FOLFIRI After Progression on FOLFIRI Plus Bevacizumab in KRAS(Kirsten Rat Sarcoma) Wild-Type Metastatic Colorectal Cancer..
panitumumab; irinotecan hydrochloride; fluorouracil; leucovorin calcium

Mucinous Adenocarcinoma of the Colon, Mucinous Adenocarcinoma of Clinical Trial using Akt inhibitor MK2206; laboratory biomarker analysis; pharmacological study

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Phase 2 Study of MK-2206 in Previously Treated Metastatic Colorectal Cancer Patients Enriched for PTEN Loss and PIK3CA Mutation.
Akt inhibitor MK2206; laboratory biomarker analysis; pharmacological study